Pfiz­er de­tails mR­NA flu vac­cine da­ta, but re­vis­es time­line

Pfiz­er’s mR­NA flu vac­cine met both pri­ma­ry end­points in the 18- to 64-year-old pop­u­la­tion in an on­go­ing Phase III tri­al, the com­pa­ny an­nounced on Tues­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER